Credit Suisse’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-746,300
| Closed | -$46.5M | – | 3676 |
|
|
2021
Q4 | $46.5M | Buy |
746,300
+176,000
| +31% | +$10.3M | 0.02% | 681 |
|
|
2021
Q3 | $33.7M | Buy |
570,300
+63,400
| +13% | +$4.18M | 0.02% | 818 |
|
|
2021
Q2 | $33.6M | Sell |
506,900
-411,400
| -45% | -$26.8M | 0.02% | 879 |
|
|
2021
Q1 | $58M | Sell |
918,300
-1,595,100
| -63% | -$99.2M | 0.03% | 641 |
|
|
2020
Q4 | $156M | Buy |
2,513,400
+407,200
| +19% | +$25M | 0.08% | 278 |
|
|
2020
Q3 | $127M | Buy |
2,106,200
+692,700
| +49% | +$41.7M | 0.08% | 283 |
|
|
2020
Q2 | $83.1M | Buy |
1,413,500
+511,100
| +57% | +$30.6M | 0.06% | 335 |
|
|
2020
Q1 | $50.3M | Sell |
902,400
-195,500
| -18% | -$11.9M | 0.04% | 433 |
|
|
2019
Q4 | $70.5M | Buy |
1,097,900
+241,800
| +28% | +$13.8M | 0.05% | 398 |
|
|
2019
Q3 | $43.4M | Sell |
856,100
-61,400
| -7% | -$2.89M | 0.04% | 523 |
|
|
2019
Q2 | $41.6M | Sell |
917,500
-212,100
| -19% | -$9.88M | 0.04% | 533 |
|
|
2019
Q1 | $53.9M | Sell |
1,129,600
-345,300
| -23% | -$17.2M | 0.05% | 395 |
|
|
2018
Q4 | $76.7M | Buy |
1,474,900
+1,011,900
| +219% | +$54.4M | 0.08% | 253 |
|
|
2018
Q3 | $28.7M | Sell |
463,000
-920,700
| -67% | -$54.6M | 0.03% | 683 |
|
|
2018
Q2 | $76.6M | Buy |
1,383,700
+1,168,700
| +544% | +$63.1M | 0.08% | 257 |
|
|
2018
Q1 | $13.6M | Sell |
215,000
-75,000
| -26% | -$4.82M | 0.01% | 1070 |
|
|
2017
Q4 | $17.8M | Hold |
290,000
| – | – | 0.02% | 947 |
|
|
2017
Q3 | $18.5M | Buy |
290,000
+136,700
| +89% | +$7.98M | 0.02% | 884 |
|
|
2017
Q2 | $8.54M | Sell |
153,300
-1,056,900
| -87% | -$57.5M | 0.01% | 1294 |
|
|
2017
Q1 | $65.8M | Buy |
1,210,200
+390,200
| +48% | +$21.4M | 0.06% | 337 |
|
|
2016
Q4 | $47.9M | Buy |
820,000
+217,700
| +36% | +$11.9M | 0.05% | 423 |
|
|
2016
Q3 | $32.5M | Buy |
602,300
+402,300
| +201% | +$25.8M | 0.03% | 616 |
|
|
2016
Q2 | $14.7M | Hold |
200,000
| – | – | 0.02% | 935 |
|
|
2016
Q1 | $12.8M | Buy |
200,000
+100,000
| +100% | +$6.31M | 0.02% | 971 |
|
|
2015
Q4 | $6.88M | Hold |
100,000
| – | – | 0.01% | 1370 |
|
|
2015
Q3 | $5.92M | Sell |
100,000
-120,000
| -55% | -$7.61M | 0.01% | 1443 |
|
|
2015
Q2 | $14.6M | Buy |
220,000
+120,000
| +120% | +$7.91M | 0.01% | 1011 |
|
|
2015
Q1 | $6.45M | Sell |
100,000
-640,000
| -86% | -$40.1M | 0.01% | 1470 |
|
|
2014
Q4 | $43.7M | Buy |
740,000
+315,000
| +74% | +$17.8M | 0.04% | 527 |
|
|
2014
Q3 | $21.8M | Hold |
425,000
| – | – | 0.02% | 868 |
|
|
2014
Q2 | $20.6M | Buy |
425,000
+325,000
| +325% | +$16M | 0.02% | 919 |
|
|
2014
Q1 | $5.2M | Sell |
100,000
-161,500
| -62% | -$8.59M | 0.01% | 1723 |
|
|
2013
Q4 | $13.9M | Buy |
+261,500
| New | +$13.3M | 0.01% | 1035 |
|
|
2013
Q3 | – | Sell |
-13,500
| Closed | -$603K | – | 4207 |
|
|
2013
Q2 | $603K | Buy |
+13,500
| New | +$586K | ﹤0.01% | 3171 |
|
Other funds holding BMY
Credit Suisse's BMY Position: Q1 2024 in Review
Credit Suisse reduced its Bristol-Myers Squibb (BMY) stake by 27% in Q1 2024, selling an estimated $91.4M and leaving 4,884,813 shares worth $265M. The position accounts for 0.25% of the portfolio, ranked #68.
Credit Suisse first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $692M in Q4 2019. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.
- Credit Suisse held 4,884,813 shares of Bristol-Myers Squibb worth $265M as of Q1 2024.
- Credit Suisse sold 1,793,918 Bristol-Myers Squibb shares in Q1 2024, an estimated $91.4M.
- Bristol-Myers Squibb made up 0.25% of Credit Suisse's portfolio in Q1 2024, its #68 holding.
- Credit Suisse first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Bristol-Myers Squibb position peaked at $692M in Q4 2019.
- 2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.